AstraZeneca advances science of infectious disease protection at IDWeek 2024
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Subscribe To Our Newsletter & Stay Updated